SignatureFD’s Aerie Pharmaceuticals AERI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-395
Closed -$6K 3455
2022
Q3
$6K Buy
+395
New +$4.59K ﹤0.01% 2405
2022
Q2
Sell
-141
Closed -$1K 3433
2022
Q1
$1K Buy
+141
New +$1.09K ﹤0.01% 3108
2021
Q4
Sell
-67
Closed -$1K 3345
2021
Q3
$1K Sell
67
-88
-57% -$1.29K ﹤0.01% 2986
2021
Q2
$2K Buy
+155
New +$2.66K ﹤0.01% 2652
2019
Q3
Sell
-125
Closed -$4K 2241
2019
Q2
$4K Hold
125
﹤0.01% 1645
2019
Q1
$6K Hold
125
﹤0.01% 1560
2018
Q4
$5K Hold
125
﹤0.01% 1557
2018
Q3
$8K Hold
125
﹤0.01% 1449
2018
Q2
$8K Buy
+125
New +$6.99K ﹤0.01% 1462
2016
Q4
Sell
-258
Closed -$10K 1337
2016
Q3
$10K Buy
+258
New +$5.69K ﹤0.01% 1036

SignatureFD's AERI Position: Q4 2022 in Review

SignatureFD sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 395 shares — an estimated $6K sold.

SignatureFD first reported a position in AERI in Q3 2016 and held it in 10 quarters. The position peaked at $10K in Q3 2016. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • SignatureFD reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • SignatureFD sold 395 Aerie Pharmaceuticals shares in Q4 2022, an estimated $6K.
  • SignatureFD first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 10 quarters.
  • SignatureFD's Aerie Pharmaceuticals position peaked at $10K in Q3 2016.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on SignatureFD's 13F filing for Q4 2022, filed 30 Jan 2023.